Press Releases InflaRx N.V.

Equities

IFRX

NL0012661870

Market Closed - Nasdaq Other stock markets 02:00:01 07/05/2024 am IST			5-day change	1st Jan Change
1.295 ^USD	-6.16%		-6.83%	-20.55%

21/03	Transcript : InflaRx N.V. - Special Call
21/03	InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024	30/04	AQ
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed	26/04	PU
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K	26/04	PU
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event	24/04	AQ
InflaRx N : News Conference Call March 2024	21/03	PU
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans	21/03	AQ
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024	19/03	AQ
InflaRx Appoints Jan Medina as Head of Investor Relations	22/02	AQ
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients	25/01	GL
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904	04/01	AQ
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	06/11	AQ
InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	01/11	PU
INFLARX N : UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2023 - Form 6-K	01/11	PU
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	01/11	AQ
InflaRx N : Desired blocking activity (>90%) of C5a-induced neutrophil activation at disease relevant C5a levels 24 hours post administration for doses of 30 mg to 240 mg - Form 6-K	11/23/11	PU
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904	11/23/11	AQ
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)	30/23/30	AQ
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update	10/23/10	AQ
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer	28/23/28	AQ
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients	21/23/21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases InflaRx N.V.

Equities

IFRX

NL0012661870

Press Releases

Filters